CA Patent

CA2906812A1 — Improved compositions for treating muscular dystrophy

Assigned to Sarepta Therapeutics Inc · Expires 2014-09-18 · 12y expired

What this patent protects

Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.

USPTO Abstract

Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2906812A1
Jurisdiction
CA
Classification
—
Expires
2014-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.